Accelerating Clinical Translation of Novel Anti-Tumor Drugs – A One-Stop Efficacy Evaluation Platform Based on Highly Predictive CDX Models

• Industry Pain Point: Traditional subcutaneous xenograft tumor models feature low clinical relevance and significant deviations in pharmacodynamic responses, making it difficult to meet the R&D demands for immunotherapies and targeted drugs.
• Value Proposition: Leveraging a standardized CDX model library and a multi-dimensional detection system, we deliver highly clinically translatable pharmacodynamic data and shorten the R&D cycle by more than 30%.

1、Service Overview

CDX models (Cell-Derived Xenografts) serve as a core tool for preclinical anti-tumor drug evaluation. However, traditional subcutaneous models lack the support of a tumor microenvironment, resulting in a pharmacodynamic prediction accuracy of less than 40% . Jennio Biotech recreates the tissue-specific tumor microenvironment through its orthotopic/metastatic CDX model construction technology. Combined with multi-dimensional assessments including in vivo imaging and pathology, the clinical relevance of pharmacodynamic data is significantly enhanced.

2、Our Services

Model Construction and Customization

• Subcutaneous Models: Suitable for primary screening. 81 lung cancer cell lines including Hela and H358 are available, supporting tumor formation within 7 days.
• Orthotopic Models: 38 types of orthotopic models such as liver cancer (HepG2-luc) and gastric cancer (MKN45-luc), which simulate the characteristics of clinical primary tumor foci and tumor metastasis.
• Metastatic Models: Pulmonary metastatic models established via tail vein injection, used for evaluating drugs against tumor cell metastasis.

Pharmacodynamic Evaluation Indices

• Basic Indices: Body weight, tumor volume (TV), relative tumor volume (RTV), T/C value (relative tumor proliferation rate), tumor weight, tumor growth inhibition rate (TGI%).
• Advanced Assays: In vivo fluorescence imaging (dynamic monitoring of tumor burden), histopathology (target expression verification via HE/IHC), ELISA (serum inflammatory factors).
• Customized Analyses: Flow cytometry for immune cell infiltration, drug-resistant cell line model establishment.

Cell Resource Library Support

• Covering 15 cancer types including lung cancer (81 cell lines), colorectal cancer (42 cell lines) and leukemia (50 cell lines) , we provide STR authentication and drug resistance prescreening data.

3、Technology Platforms and Advantages

Core Platforms

• Standardized Model Library: 1000+ human/murine cell lines, supporting subcutaneous/orthotopic/intravenous inoculation.
• In Vivo Imaging Platform: Quantitative monitoring of tumor fluorescent signals (e.g., MKN45-Luc gastric cancer orthotopic model, HepG2-Luc liver cancer orthotopic model, etc. ), with a lower limit of detection (LLOD) of 10³ p/s/cm²/sr.
• Pathological Analysis Platform: Automated HE staining and immunohistochemistry (IHC). Quantitative pathological reports are issued within 2 to 3 weeks after sample collection.

Differentiated Advantages

• Enhanced Clinical Relevance: Orthotopic models closely mimic the primary microenvironment of in vivo tumor foci, assess the pharmacodynamic effects of drugs on lesions following their systemic metabolic circulation, and thus markedly enhance the clinical accuracy of pharmacodynamic evaluation.
• Full-Cycle Support: GLP-aligned quality control is implemented throughout the entire process, from cell inoculation to the delivery of pharmacodynamic reports.
• Cost Optimization: The unit price for model establishment is as low as RMB 600 per animal (for nude mouse CDX models), supporting high-throughput screening.

4、Service Process

• Requirement Confirmation (1 working day): Customized protocol design (cell line selection/administration regimen).
• Model Establishment (7–21 days): Real-time provision of tumor formation imaging and body weight monitoring data.
• Pharmacodynamic Assay Implementation: Tumor measurements conducted twice weekly, with in vivo imaging at key time points.
• Data Delivery: Including raw imaging data, pathological sections, statistical analysis of raw data (body weight, TGI, survival curves, etc.), and a project summary report.

An online progress tracking system is available throughout the entire process, with responses to data review requests provided within 48 hours.

5、Quality Control and Compliance

• Animal Welfare: Compliant with AAALAC standards and supervised by IACUC.
• Data Traceability: Electronic archiving of experimental records, supporting third-party audits.
• GLP-aligned Processes: Implement GLP standard operating procedures (formal certification pending).

6、Case Studies

• Case 1:Pharmacodynamic Evaluation of Orthotopic Liver Cancer Model
  • Model: Orthotopic transplantation of HepG2-luc (NCG mice).
  • Intervention: Lenvatinib treatment for 21 days.
  • Results: Tumor signal reduced by 68% and tumor weight decreased by 72% in the treatment group.
• Case 2: Pharmacodynamic Evaluation of Orthotopic Gastric Cancer Model
  • Model: MKN45-luc orthotopic model.
  • Regimen: Oxaliplatin.
  • Results: The T/C value reached 28%, which was significantly superior to that of the monotherapy group.

For more cases, please visit the Jennio CDX Model Special Topic Database.

7、Collaboration Advantages

• High Turnaround Efficiency: Standardized processes ensure the delivery of pharmacodynamic reports within 21 days (industry average: 35 days).
• One-Stop Solution: Covering the entire workflow from model establishment to pharmacodynamic evaluation and mechanism research (e.g., immune microenvironment analysis).
• Flexible Customization: Supporting customized models for the evaluation of immune checkpoint inhibitors such as PD-1/CTLA-4.

8、FAQ

• Q1: Are humanized immune system models supported?

A: Yes. We can provide NCG mice engrafted with human PBMCs or CD34+ hematopoietic stem cells for the evaluation of immunity-related drugs.

• Q2：Is the establishment of drug-resistant strain models available?

A: Yes, A cell line library resistant to cisplatin/paclitaxel has been established, with a turnaround time of 4–6 weeks.

9、Laboratory Highlights

• 10,000-class purification, capacity for 5,000 cages, constant temperature and humidity environment.
• Capable of detecting 10³-level cellular fluorescence signals, supporting dynamic drug efficacy tracking.

View More

10、Contact Us

• E-mail:3691125803@qq.com
• Tel: +86 18802035152(24-hour response)
• Free access to the Technical White Paper on CDX Model Construction(covering practical guidelines for 50+ cancer types).
• 10% off on your first order; a customized plan will be provided within 48 hours after submitting the requirement form.